Document is current

Article History

Received: 11 October 2025

Accepted: 26 February 2026

First Online: 18 March 2026

Declarations

:

: LQY is a member of the research group from China Resources Double-Crane Limin Pharmaceutical Co., Ltd (Jinan, China), he declares no competing interests. HCP is a member of the research group from China Resources Double-Crane Limin Pharmaceutical Co., Ltd (Jinan, China), he declares no competing interests. WQH is a member of the research group from China Resources Double-Crane Limin Pharmaceutical Co., Ltd (Jinan, China), he declares no competing interests. All other authors declare no competing interests.

: This study was performed abiding by the Declaration of Helsinki, Good Clinical Practice (GCP), and guidelines of the China National Medical Products Administration (NMPA). The protocol, informed consent, and other relevant documents were approved by the independent ethics committee of Wuhan Pulmonary Hospital.

: Written informed consent was obtained from all participants prior to their enrollment in the study.

: All researchers, participants, institutions and the sponsors have agreed to publish the results of this study in this journal.

: The datasets used and/or analyzed for the current study are available from the corresponding authors upon reasonable request.

: Not applicable.

: LG participated in the conception and design and contributed to quality control throughout the study. YHG contributed to the writing of the manuscript. ZM contributed to the study organization and implementation. PY and LXW were in charge of the management of study drugs. PZX, WJ, and XYF were responsible for disposition of biological samples. As the sponsor-affiliated authors, LQY, HCP, and WQH were involved only in study coordination and administrative support. All authors read and approved the final manuscript.